Chemomab Therapeutics Ltd.
CMMBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Chemomab Therapeutics Ltd. focuses on Biotechnology services and products. Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Valued at $19.9M, CMMB is a micro-cap name in its sector. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Market Cap
$19.9M
Beta
0.76
P/E (TTM)
—
P/E (Fwd)
-90.33
EPS (TTM)
$-0.96
EPS (Fwd)
$-0.03
ROE
-82.2%
ROA
-46.3%
Cash
$6.7M
Total Debt
$0
Free CF
-$6.2M
52W Change
-11.2%
Annual Financials
Cash vs Debt
Where CMMB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CMMB finished 55.11% above its 150-day moving average ($1.76) and 48.37% above its 200-day moving average ($1.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CMMB overbought or oversold?
At the September 3, 2026 close, CMMB's RSI(14) was 95.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Chemomab Therapeutics Ltd. reports $6.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$6.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -82.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CMMB.